Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 16, 2024
Distillery Therapeutics
Inhibiting FST-IGF1R interaction for neuropathic pain
BioCentury | Nov 27, 2024
Discovery & Translation
Science Spotlight: Reducing immune rejection of stem cell-derived therapies
BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos
BioCentury | Oct 24, 2024
Product Development
Vaderis: A case study in navigating the orphan drug development maze
Company went from idea to clinical proof of concept for
BioCentury | Oct 21, 2024
Product Development
EGFR: A best-in-class strategy study
The target is one of industry’s most notable case studies in continued product differentiation and market growth
BioCentury | Aug 28, 2024
Product Development
Clinical Report: U.K. details plans to improve clinical trial infrastructure
Plus: Neurocrine’s schizophrenia therapy, Medicxi-backed Vaderis’ treatment for rare vascular disorder both look to advance; plus a miss for Leo’s Timber
BioCentury | Apr 10, 2024
Finance
How Goldman Sachs’ life sciences strategy aims to scale private biotechs
Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer
BioCentury | Apr 5, 2024
Finance
Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal
Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
Items per page:
1 - 10 of 675